Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis.

Autor: Goel U; Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA., Dima D; Cleveland Clinic Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas, USA., Davis J; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas, USA.; Department of Hematology/Medical Oncology, The Medical University of South Carolina, Charleston, South Carolina, USA., Ahmed N; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas, USA.; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Shaikh H; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas, USA.; University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, USA., Lochner J; University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa, USA., Abdallah AO; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas, USA.; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Khouri J; Cleveland Clinic Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA., Hashmi H; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas, USA.; Myeloma & Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Anwer F; Cleveland Clinic Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas, USA.
Jazyk: angličtina
Zdroj: European journal of haematology [Eur J Haematol] 2024 Dec; Vol. 113 (6), pp. 817-823. Date of Electronic Publication: 2024 Aug 27.
DOI: 10.1111/ejh.14293
Abstrakt: Clinical trials evaluating chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (RRMM) have typically excluded patients with AL amyloidosis. As a result, there are limited data on the safety and efficacy of CAR T-cell therapy in this patient population. We retrospectively reviewed eight consecutive patients with RRMM and AL amyloidosis who were treated with standard of care CAR T-cell therapy. Cytokine release syndrome was seen in 75% of patients (grade ≥3: 0%) and immune effector cell-associated neurotoxicity syndrome (grade 1) in only one patient. Low-grade cytopenias were common (any grade/grade ≥3: neutropenia 62.5%/37.5%, anemia 37.5%/0%, thrombocytopenia 25%/0%). CAR T-cell therapy led to rapid and deep responses with a median time to best response of 43 days and a hematologic very good partial response or better rate of 62.5%. Overall, we found that commercial CAR T-cell therapy was feasible, and effective in patients with RRMM and concurrent AL amyloidosis.
(© 2024 The Author(s). European Journal of Haematology published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: